Avanos Medical Announced That The CMS Has Issued Its Final Medicare Hospital OPPS And Medicare ASC Payment System Rule For 2025; Effective Jan. 1, 2025, Implements The Non-Opioids Prevent Addiction In The Nation Act That Mandates Separate Medicare...
Avanos Medical Announced That The CMS Has Issued Its Final Medicare Hospital OPPS And Medicare ASC Payment System Rule For 2025; Effective Jan. 1, 2025, Implements The Non-Opioids Prevent Addiction In The Nation Act That Mandates Separate Medicare...
Both ON-Q and ambIT infusion delivery systems each received a unique, brand-specific Healthcare Common Procedure Coding System (HCPCS) code eligible for separate payment in the HOPD and ASC settings. This decision by CMS is a pivotal step towards enhancing access to clinically proven non-opioid treatments for Medicare beneficiaries in HOPD and ASC settings.Avanos Medical Announced That The CMS Has Issued Its Final Medicare Hospital OPPS And Medicare ASC Payment System Rule For 2025; Effective Jan. 1, 2025, Implements The Non-Opioids Prevent Addiction In The Nation Act That Mandates Separate Medicare Payment For Qualifying Non-Opioid Drugs And Devices
avanos medical宣布，康哲药业已发布其2025年医院门诊潜在支付系统（OPPS）和医疗协助手术中心（ASC）支付系统的最终医疗保险和医疗补助服务中心（CMS）法规；自2025年1月1日起生效，执行全国非鸦片类药物预防成瘾法案，要求符合条件的非鸦片类药物和设备获得单独的医疗保险支付。
Avanos Medical, Inc. (NYSE:AVNS) announced today that the Centers for Medicare and Medicaid Services (CMS) has issued its final Medicare Hospital Outpatient Prospective Payment System (OPPS) and Medicare Ambulatory Surgical Center (ASC) Payment System rule for 2025. This rule, effective Jan. 1, 2025, implements the Non-Opioids Prevent Addiction in the Nation (NOPAIN) Act that mandates separate Medicare payment for qualifying non-opioid drugs and devices.
avanos medical, inc.（纽交所：AVNS）今日宣布，美国医疗保险和医疗补助服务中心（CMS）已发布其2025年医院门诊潜在支付系统（OPPS）和医疗协助手术中心（ASC）支付系统的最终规则。该规则自2025年1月1日起生效，实施预防全国成瘾非鸦片类药物法案，要求符合条件的非鸦片类药物和设备获得单独的医疗保险支付。
The NOPAIN Act, passed as part of the Consolidated Appropriation Act of 2023, aims to increase patient access to non-opioid drugs and devices used to manage pain in Hospital Outpatient (HOPD) and ASC settings by providing additional Medicare reimbursement for qualifying non-opioid items.
2023年通过的整体拨款法案的一部分，NOPAIN法案旨在通过为符合条件的非鸦片类物品提供额外的医疗保险补偿，在医院门诊潜在支付系统（HOPD）和ASC环境中增加患者获得用于管理疼痛的非鸦片类药物和设备的渠道。
In the final rule, CMS confirmed that both the Avanos ON-Q elastomeric infusion pump and the Avanos ambIT disposable electronic infusion pump non-opioid pain management delivery systems meet qualifying requirements, marking a significant milestone as both become eligible for separate payment for the first time under the NOPAIN Act. HOPDs and ASCs that use these products will receive separate Medicare reimbursement in addition to the related APC payments beginning January 1, 2025.
在最终规则中，CMS确认Avanos ON-Q弹性输液泵和Avanos ambIt一次性电子输液泵非鸦片类疼痛管理传递系统均符合资格要求，这标志着两者首次根据NOPAIN法案有资格获得单独支付，HOPD和ASC使用这些产品的医疗中心将在2025年1月1日起开始除了相关APC支付之外获得单独的医疗保险支付。
Both ON-Q and ambIT infusion delivery systems each received a unique, brand-specific Healthcare Common Procedure Coding System (HCPCS) code eligible for separate payment in the HOPD and ASC settings. This decision by CMS is a pivotal step towards enhancing access to clinically proven non-opioid treatments for Medicare beneficiaries in HOPD and ASC settings.
ON-Q和ambIt输液传递系统分别获得了在HOPD和ASC环境中获得单独支付的独特品牌特定医疗通用程序编码系统（HCPCS）代码。CMS的这一决定是提升在HOPD和ASC环境中为医疗保险受益人提供经临床验证的非鸦片类治疗方法的重要一步。
The payment limitation calculated and published by CMS is up to $2,284.98 for the ON-Q infusion system and up to $2,284.98 for the ambIT infusion system. The new unique HCPCS code C9804 for ON-Q and HCPCS code C9806 for ambIT can be used on claim submissions beginning for services rendered on January 1, 2025.
CMS计算并发布的支付限制为ON-Q输液系统最高为2284.98美元，ambIt输液系统最高为2284.98美元。ON-Q的新HCPCS代码为C9804，ambIt的HCPCS代码为C9806，可以在2025年1月1日提供的服务的索赔提交中使用。
The NOPAIN Act mandates that CMS provide separate payment for qualified non-opioid treatments through December 31, 2027 when provided with a covered surgical procedure. The ON-Q and ambIT devices are now the first and only infusion pain pumps included under this policy, which aims to reduce reliance on opioids in postoperative care. CMS will review and approve eligible products on an annual basis during this 3-year program. This initiative is part of a broader strategy by CMS to combat the opioid crisis by promoting safer pain management alternatives.
NOPAIN法案要求康哲药业在提供符合条件的非阿片类治疗时，通过2027年12月31日为进行覆盖手术的患者提供单独支付。 ON-Q和ambIt设备现在是第一个也是唯一一个包含在该政策下的输注疼痛泵，旨在减少在术后护理中对阿片类药物的依赖。在这项为期3年的计划期间，康哲药业将每年审查和批准符合条件的产品。该倡议是康哲药业通过推广更安全的疼痛管理替代方案来应对阿片类药物危机的更为广泛的策略的一部分。
